AI illustration · not actual product photoDetails from the source.
This catalogue entry records FOXO4, 10 mg × 10 vials (SKU F410), using the supplied source listing. The cited dossier describes: Preclinical FOXO4-DRI research investigates senescent-cell biology and senolytic effects. Experiments include cultured cells and animal models of chemotherapy-related tissue injury, aging, and age-associated Leydig-cell changes. A separate study examined FOXO4-DRI in vitro in expanded human chondrocytes. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- F410
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Identity unresolved. The source label is exactly “FOXO4” (SKU F410; *10vials; listed price 355 per 10 vials, currency not stated). FOXO4 is a transcription factor, while FOXO4-DRI is a distinct engineered peptide. The catalogue label does not establish that this vial is FOXO4-DRI or even that it contains a peptide; no exact sequence, stereochemistry, formulation, or manufacturer is provided.
Biological mechanism
For the specific FOXO4-DRI agent studied in publications only, proposed mechanism is competition with FOXO4 for p53 binding. In studied senescent cells this was associated with p53 nuclear exclusion and caspase-associated apoptosis. This mechanism cannot be assigned to the catalogued “FOXO4” vial without evidence that the contents are FOXO4-DRI.
Research focus
Preclinical FOXO4-DRI research investigates senescent-cell biology and senolytic effects. Experiments include cultured cells and animal models of chemotherapy-related tissue injury, aging, and age-associated Leydig-cell changes. A separate study examined FOXO4-DRI in vitro in expanded human chondrocytes.
Potential applications in the evidence
Only investigational areas: senescent-cell clearance in cell models; effects in mouse models of aging, tissue injury, and Leydig-cell function; and reduction of senescence markers in laboratory-expanded human chondrocytes. These are not established clinical applications or evidence of efficacy for this catalogue item.
Human evidence
The available human-derived evidence is laboratory-based: one study examined expanded human chondrocytes in vitro, and another examined human testis samples but administered FOXO4-DRI only to cells and mice. These are not human treatment trials. The ClinicalTrials.gov search for FOXO4-DRI returned no records when checked. Human clinical efficacy, dosage, safety, and therapeutic benefit have not been established.
Known and potential effects
No human adverse-effect profile is established. In vitro and animal studies of FOXO4-DRI report apoptosis in studied senescent cells and changes in measured tissue or hormone markers. These findings do not establish effects or safety in people or for the catalogued product. Potential effects in non-target cells and tissues remain uncertain.
Safety and contraindications
Human safety, contraindications, and long-term effects are unknown. The intended apoptosis mechanism and interaction with p53-related biology raise unresolved questions about non-target cells and tissues. An aged-mouse study specifically calls for further systematic safety and tolerability assessment, including possible muscle effects. No specific contraindications for the exact vial can be verified. Do not infer human-use safety from preclinical findings.
U.S. FDA / regulatory status
The reviewed FDA Drugs@FDA resource did not establish an FDA-approved FOXO4-DRI product, and the supplied label does not identify any approved ingredient or branded formulation. The FDA status of this exact vial cannot be verified because its manufacturer, identity, formulation, provenance, jurisdiction, lot, and approval/application number are unknown. The catalogue alone does not establish that the vial is compounded or research-only. No approval can be inferred or transferred from a different active ingredient or product.
Evidence limitations
FOXO4-DRI findings are preclinical; use of human-derived cells or tissue is not human clinical evidence. Animal and in-vitro findings cannot establish clinical efficacy, safety, or long-term outcomes. FOXO4-DRI evidence must not be attributed to the differently labeled “FOXO4” vial without confirming its identity. The exact product’s peptide status, sequence, purity, formulation, provenance, quality, and regulatory status remain unverified.
Supporting sources
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Cell; PubMed Central / National Library of Medicine · Peer-reviewed primary research. Supports: Distinction of FOXO4-DRI from FOXO4; proposed FOXO4-p53 mechanism; cellular and animal preclinical findings; absence of human treatment evidence and safety limitations.
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging; PubMed Central / National Library of Medicine · Peer-reviewed primary research. Supports: Human testis tissue and in-vitro/aged-mouse findings; proposed Leydig-cell mechanism; authors’ stated need for broader safety assessment and study limitations.
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes Frontiers in Bioengineering and Biotechnology · Peer-reviewed primary research. Supports: In-vitro work in human-derived chondrocytes and limitations on extrapolating those results to patients.
- ClinicalTrials.gov search for FOXO4-DRI U.S. National Library of Medicine · Government clinical-trial registry search. Supports: Search results showed no records for the exact FOXO4-DRI search term at the time checked; this does not prove that no unregistered or differently named study exists.
- Drugs@FDA: FDA-Approved Drugs U.S. Food and Drug Administration · Official FDA drug-approval database. Supports: Defines Drugs@FDA as a database of FDA-approved drugs and provides the official resource reviewed for approval-status verification; it does not establish approval of the unidentified supplier vial.
- Bulk Drug Substances Used in Compounding U.S. Food and Drug Administration · Official FDA regulatory information. Supports: FDA limits concerning bulk drug substances used in compounding; this does not establish that the catalogued item is compounded.